TCS Recognized as a Leader in the IDC MarketScape for Worldwide Life Science R&D ITO Services

MUMBAI: Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been named as a Leader in the IDC MarketScape, for Worldwide Life Science R&D ITO Services[1].

The report highlights that, “TCS is focusing on an advisory-led transformation approach for higher digital adoption and value creation with a focus on IP-based digital health, real-world evidence, scientific ‘collaboration’, connected smart labs, data-driven clinical development, digital clinical trials, automation, and regulatory intelligence.” It goes on to say that, “TCS has been recognized for the strategic direction that it brings to IT transformation initiatives, its flexibility and agility despite its scale, and its end-to-end project delivery capabilities.”

“TCS leverages its domain knowledge, intellectual property and contextual solutions designed using the combinatorial power of cutting-edge technologies to help clients transform and scale their R&D initiatives and achieve their purpose-driven goals,” said Vikas Jain, Global Co-Head, Life Sciences, TCS. “This leadership position is a reflection of our strategies, capabilities, investments in intellectual property, and the resultant market success.”

TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies. TCS offers a full set of services spanning advisory, digital transformation, and cognitive business operations in areas such as digitization of clinical trials, paperless and integrated lab environment, blockchain-enabled clinical supply chain, AI enabled case processing, and discovery collaboration. The solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation, Internet of Things and cloud to fully digitize life sciences value chain.

TCS has also invested heavily in research and innovation capabilities in the life sciences domain. Its genomics labs offer capabilities such as DNA sequencing, marker validation, and translational research.

A critical transformation lever is TCS’ flagship intellectual property, TCS ADD, a cloud-native, cognitive platform that reimagines the end-to-end drug development value chain using digital technologies to enhance patient and user experience and improve clinical trial outcomes. The platform leverages the TCS Decision Fabric™ AI engine and spans data standardization, data management, analytics and insights, safety, regulatory, supply management, patient and site engagement, and devices and connections.

Comments are closed.